2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Chronic Myelogenous Leukemia
Chronic Myelogenous Leukemia (CML) presents a complex battleground in cancer research, marked by the relentless proliferation of myeloid cells within the blood and bone marrow. While traditional treatments like chemotherapy and stem cell transplants have been mainstays, the advent of targeted therapies has heralded a new era. Tyrosine kinase inhibitors (TKIs), such as Imatinib, stand as pivotal weapons in this fight, honed to specifically counter the genetic anomaly, the Philadelphia chromosome. Yet, the battle is far from won; challenges persist, including drug resistance and lingering side effects. Current investigations in CML delve into the intricate mechanisms of resistance, hunt for fresh therapeutic targets, and experiment with combination therapies to bolster long-term patient outcomes and enhance their quality of life. The frontier of precision medicine beckons, promising tailored and potent treatments in the ongoing war against CML.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China